Company / Capital Expenditures
TriSalus Life Sciences, Inc. Capital Expenditures History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$345.0K
FY2025
5-year range
$345.0K / $655.0K
FY2023-FY2025
Trend
-41.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $655,000 to $345,000 over the past 2 years.
Based on SEC 10-K filings.
$345,000 in FY2025.
Declined from $655,000 to $345,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, capital expenditures decreased 41.3% year-over-year.
Company context
Key Data Points
- Altman Z-Score -2.11 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $345.0K | -41.3% |
| FY2024 | $588.0K | -10.2% |
| FY2023 | $655.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026